LVGN7409

BIOLOGICAL2 trials

Sponsors

Lyvgen Biopharma Holdings Limited

Conditions

Cancer

Phase 1

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

CompletedNCT04635995

Lyvgen Biopharma Holdings LimitedCancer

Start: 2020-12-11End: 2025-12-31Updated: 2026-05-19

Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy

CompletedNCT05152212

Lyvgen Biopharma Holdings LimitedCancer

Start: 2021-09-29End: 2023-12-19Updated: 2024-04-22

Related Papers

Early safety and efficacy from a phase I open-label clinical study of LVGN7409 (CD40 agonist antibody) in patients with advanced or metastatic malignancies.

Journal of Clinical Oncology2022-06-013 citations